In this study, we demonstrate both a novel antiapoptotic role for CIP2A in CML pathogenesis and a key role for BCL-XL in survival of CML cell lines and in primary CD34+ cells from patients. Here, CIP2A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.